Home > Cardiology > ACC 2021 > Ischaemic Heart Disease > No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial

No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial

Presented By
Prof. William Schuyler Jones , Duke Clinical Research Institute, USA
Conference
ACC 2021
Trial
ADAPTABLE
Low-dose aspirin (81 mg daily) was associated with similar rates of ischaemic events and bleeding events as high-dose aspirin (325 mg daily) in preventing stroke, myocardial infarction (MI), or death in patients with known atherosclerotic cardiovascular disease (ASCVD) according to the findings of the ADAPTABLE trial, but a high degree of cross over adds complexity to the results [1,2]. Prof. William Schuyler Jones (Duke Clinical Research Institute, NC, USA) presented the ADAPTABLE study (NCT02697916), which aimed to compare the effectiveness of 2 doses of aspirin at preventing major adverse cardiac events (MACE) in patients with ASCVD (defined as a history of prior MI, prior coronary angiography showing ≥75% stenosis of at least 1 epicardial coronary vessel or prior coronary revascularisation procedures, or history of chronic heart disease). The...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on